Search

Your search keyword '"Connolly, Stuart"' showing total 566 results

Search Constraints

Start Over You searched for: Author "Connolly, Stuart" Remove constraint Author: "Connolly, Stuart" Database Unpaywall Remove constraint Database: Unpaywall
566 results on '"Connolly, Stuart"'

Search Results

1. Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry

3. Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction

5. Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials

6. ANDEXANET ALFA VS NON-SPECIFIC TREATMENTS FOR INTRACEREBRAL HEMORRHAGE IN PATIENTS TAKING FACTOR XA INHIBITORS – INDIVIDUAL PATIENT DATA ANALYSIS OF ANNEXA-4 AND TICH-NOAC

7. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes

8. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials

9. Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials

10. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

11. Cerebral Microbleeds and Asundexian in Non-cardioembolic Ischemic Stroke: Secondary Analyses of the PACIFIC-STROKE Randomized Trial

13. Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III

14. Small-Volume Blood Collection Tubes to Reduce Transfusions in Intensive Care

15. Atrial Fibrillation Recurrence in Patients With Transient New-Onset Atrial Fibrillation Detected During Hospitalization for Noncardiac Surgery or Medical Illness

16. Benzodiazepine-Free Cardiac Anesthesia for Reduction of Postoperative Delirium (B-Free): A Protocol for a Multi-centre Randomized Cluster Crossover Trial

17. Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation

19. PO-03-071 SHORT-TERM COLCHICINE AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION – A RANDOMIZED, PLACEBO-CONTROLLED TRIAL

20. Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality

21. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation

22. Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial

24. Contributors

25. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

26. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores

28. Response to the Letter by Spurling and Colleagues

29. Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials

30. A hybrid automated event adjudication system for clinical trials

31. Abstract WP126: Predictors Of Intracranial Hemorrhage Volume Expansion In Patients Receiving Factor Xa Inhibitors In The Annexa-4 Trial

32. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

33. Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

34. Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation

35. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

36. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial

37. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

40. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial

41. Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

42. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

43. Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding

44. ABC-AF STROKE AND BLEEDING SCORES ARE USEFUL TOOLS TO ESTIMATE THE BALANCE BETWEEN BENEFITS AND RISKS WITH DIFFERENT ANTITHROMBOTIC TREATMENTS IN PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE AND RE-LY TRIALS

45. Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

47. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care

48. Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration

49. Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke

50. Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial

Catalog

Books, media, physical & digital resources